| amiodarone vs class I drugs | No demonstrated result suggested Pro-arrhythmia by 70% (not demonstrated) suggested Adverse events leading to treatment discontinuation by 67% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.75 [0.46 1.22] | p=1.00 | 0 | 405 | 2 | AFFIRM Substudy (amiodarone vs class I drugs),AFFIRM Substudy (sotalol vs class I drugs), | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | 0.63 [0.18 2.20] | p=1.00 | 0 | 222 | 1 | AFFIRM Substudy (amiodarone vs class I drugs), | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 0.30 [0.16 0.57] | p=0.04 | 0 | 531 | 2 | AFFIRM Substudy (sotalol vs class I drugs),AFFIRM Substudy (amiodarone vs class I drugs), | | All cause death | 0.59 [0.34 1.03] | p=1.00 | 0 | 405 | 2 | AFFIRM Substudy (amiodarone vs class I drugs),AFFIRM Substudy (sotalol vs class I drugs), | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 0.33 [0.18 0.61] | p=0.04 | 0 | 275 | 1 | AFFIRM Substudy (amiodarone vs class I drugs), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs disopyramide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.55 [0.21 1.44] | p=1.00 | 0 | 76 | 1 | Villani, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | no data | | All cause death | 1.17 [0.02 60.61] | p=1.00 | 0 | 76 | 1 | Villani, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 0.35 [0.09 1.40] | p=1.00 | 0 | 76 | 1 | Villani, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs placebo | No demonstrated result suggested Atrial fibrillation recurrence by 47% (not demonstrated) suggested Adverse events leading to treatment discontinuation by 459% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.53 [0.35 0.81] | p=0.04 | 0 | 673 | 4 | Channer,GEFACA,Kochiadakis (amiodarone vs placebo),SAFE-T (amiodarone vs placebo), | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 2.06 [0.62 6.82] | p=1.00 | 0 | 673 | 4 | Channer,GEFACA,Kochiadakis (amiodarone vs placebo),SAFE-T (amiodarone vs placebo), | | All cause death | 1.60 [0.53 4.86] | p=1.00 | 0 | 673 | 4 | Channer,GEFACA,Kochiadakis (amiodarone vs placebo),SAFE-T (amiodarone vs placebo), | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 5.59 [1.24 25.27] | p=0.04 | 0 | 274 | 3 | Channer,GEFACA,Kochiadakis (amiodarone vs placebo), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs propafenone | No demonstrated result suggested Adverse events leading to treatment discontinuation by 774% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.64 [0.32 1.28] | p=1.00 | 0 | 146 | 1 | Kochiadakis a, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 1.03 [0.14 7.50] | p=1.00 | 0 | 146 | 1 | Kochiadakis a, | | All cause death | 1.03 [0.02 52.50] | p=1.00 | 0 | 146 | 1 | Kochiadakis a, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 8.74 [1.94 39.41] | p=0.04 | 0 | 146 | 1 | Kochiadakis a, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs quinidine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.40 [0.12 1.30] | p=1.00 | 0 | 54 | 1 | Vitolo, | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 0.93 [0.06 15.65] | p=1.00 | 0 | 54 | 1 | Vitolo, | | All cause death | 0.93 [0.02 48.56] | p=1.00 | 0 | 54 | 1 | Vitolo, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 0.93 [0.06 15.65] | p=1.00 | 0 | 54 | 1 | Vitolo, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs sotalol | No demonstrated result suggested Atrial fibrillation recurrence by 31% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | 0.69 [0.53 0.91] | p=0.04 | 0 | 910 | 3 | AFFIRM Substudy (amiodarone vs sotalol),Kochiadakis (amiodarone vs sotalol),SAFE-T (amiodarone vs sotalol), | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | 0.95 [0.27 3.38] | p=1.00 | 0 | 256 | 1 | AFFIRM Substudy (amiodarone vs sotalol), | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 0.61 [0.30 1.24] | p=1.00 | 0 | 943 | 3 | AFFIRM Substudy (amiodarone vs sotalol),Kochiadakis (amiodarone vs sotalol),SAFE-T (amiodarone vs sotalol), | | All cause death | 0.70 [0.42 1.17] | p=1.00 | 0 | 910 | 3 | AFFIRM Substudy (amiodarone vs sotalol),Kochiadakis (amiodarone vs sotalol),SAFE-T (amiodarone vs sotalol), | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 1.11 [0.61 2.00] | p=1.00 | 0 | 415 | 2 | AFFIRM Substudy (amiodarone vs sotalol),Kochiadakis (amiodarone vs sotalol), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs ICD | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | 1.96 [0.17 22.33] | p=1.00 | 0 | 103 | 1 | AMIOVIRT, | | Death from any cause or hospitalization for any reason | no data | | All cause death | 1.14 [0.36 3.67] | p=1.00 | 0 | 103 | 1 | AMIOVIRT, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs no treatment | No demonstrated result suggested All cause death by 31% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | 0.66 [0.42 1.03] | p=1.00 | 0 | -36 | 2 | EPAMSA,GESICA, | | Death from any cause or hospitalization for any reason | no data | | All cause death | 0.69 [0.53 0.89] | p=0.04 | 0 | -36 | 2 | EPAMSA,GESICA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| amiodarone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Sudden death | 0.87 [0.60 1.24] | p=1.00 | 0 | -54 | 3 | Hamer,Nicklas,STATCHF, | | Death from any cause or hospitalization for any reason | no data | | All cause death | 0.96 [0.74 1.25] | p=1.00 | 0 | -54 | 3 | Hamer,Nicklas,STATCHF, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| early amiodarone vs control | No demonstrated result suggested All cause death by 56% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Arrhythmic/sudden death | 0.56 [0.24 1.30] | p=1.00 | 0 | 350 | 2 | BASIS,Navarro-Lopez, | | All cause death | 0.44 [0.22 0.86] | p=0.04 | 0 | 350 | 2 | BASIS,Navarro-Lopez, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| early amiodarone vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Arrhythmic/sudden death | 0.68 [0.45 1.01] | p=1.00 | 0 | 724 | 3 | CAMIAT ,Ceremuzynski,Hockings, | | All cause death | 0.84 [0.64 1.09] | p=1.00 | 0 | 724 | 3 | CAMIAT ,Ceremuzynski,Hockings, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
